NCT06088277 Texting to Reduce Human Immunodeficiency Virus (HIV) Risk
| NCT ID | NCT06088277 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boston University |
| Condition | HIV Infections |
| Study Type | INTERVENTIONAL |
| Enrollment | 266 participants |
| Start Date | 2024-08-16 |
| Primary Completion | 2027-04-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 266 participants in total. It began in 2024-08-16 with a primary completion date of 2027-04-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a 3-year study to test the efficacy of a text message-based intervention program. Dental patients at 4 community health centers (n= 266) will be randomized to receive either text messages (TMs) regarding HIV prevention or TMs regarding overall wellness. Prior to enrolling the 266 participants, the investigators will conduct a feasibility pilot (n=20) to test the TM delivery as well as all study procedures. For both the pilot and the randomized clinical trial (RCT), recruitment will be conducted at 4 Community Health Center dental clinics (Codman Square, East Boston (both East Boston and South End locations), Geiger Gibson, and Upham's Community Health Centers). Recruitment materials (flyers and permission to contact forms) may also be made available at other clinics within the health centers. The study will enroll English and Spanish-speaking patients who have at least one risk factor for HIV but are HIV-negative. Patients enrolled in the pilot will complete self-report surveys at baseline, 1 and 2 months. Participants enrolled in the RCT will complete self-report surveys baseline, 3, 6, and 12 months after baseline; receive and respond to TM assessments during the 6-month intervention.
Eligibility Criteria
Inclusion Criteria: * Give informed consent and document consent via a signed and dated informed consent form in REDCap * Willing to comply with all study procedures and be available for the duration of the study * Be able to read either in English or Spanish * Be a dental clinic patient of record at one of our participating community health centers * Has at least one risk factor for HIV defined as self-report of at least one of the following: Men who have sex with men; multiple sex partners, or intravenous drug use Exclusion Criteria: * Self-report of having HIV infection * Participating in another HIV study or another text message study * A woman who reports having sex exclusively with women * Does not have a mobile phone or other device which can receive text messages from Agile Health * Does not have unlimited texting on their mobile plan * Has not used any type of text messaging at least once in the past month * Single item literacy screening score of 2 or below.
Contact & Investigator
Michelle Henshaw, DDS, MPH
PRINCIPAL INVESTIGATOR
Boston University Goldman School of Dental Medicine
Frequently Asked Questions
Who can join the NCT06088277 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HIV Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06088277 currently recruiting?
Yes, NCT06088277 is actively recruiting participants. Contact the research team at mhenshaw@bu.edu for enrollment information.
Where is the NCT06088277 trial being conducted?
This trial is being conducted at Boston, United States, Boston, United States.
Who is sponsoring the NCT06088277 clinical trial?
NCT06088277 is sponsored by Boston University. The principal investigator is Michelle Henshaw, DDS, MPH at Boston University Goldman School of Dental Medicine. The trial plans to enroll 266 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.